XML 315 R127.htm IDEA: XBRL DOCUMENT v3.25.2
Fair Value Measurements - Valuation Of Convertible Notes (Details)
$ / shares in Units, $ in Millions
Jun. 30, 2025
$ / shares
Dec. 31, 2024
$ / shares
Dec. 31, 2024
USD ($)
Dec. 31, 2024
Y
Dec. 31, 2024
Dec. 17, 2024
$ / shares
Dec. 31, 2023
$ / shares
Fair Value Measurements              
Aggregate principal amount | $     $ 28.3        
Convertible debt accrued interest rate         8.00%    
Par value per share (in $ per share) | $ / shares $ 0.001 $ 0.001       $ 0.001 $ 0.001
Cara Therapeutics, Inc.              
Fair Value Measurements              
Par value per share (in $ per share) | $ / shares           $ 0.001  
Convertible notes              
Fair Value Measurements              
Aggregate principal amount | $     $ 28.3        
Convertible debt accrued interest rate         8.00%    
Convertible notes | Time to Qualified/non-Qualified financing (in years)              
Fair Value Measurements              
Convertible note, measurement input       0.25      
Convertible notes | Time to IPO (in years)              
Fair Value Measurements              
Convertible note, measurement input       0.25      
Convertible notes | Time to reverse merger (in years)              
Fair Value Measurements              
Convertible note, measurement input       0.33      
Convertible notes | Interest rate (risk-free)              
Fair Value Measurements              
Convertible note, measurement input       4.37 0.0437    
Convertible notes | Conversion discount rate              
Fair Value Measurements              
Convertible note, measurement input         0.20